As of Friday close, Novo Nordisk A/S’s (NYSE:NVO) stock was up $0.01, moving up 0.01 percent to $91.30. The average number of shares traded per day over the past five days has been 4,906,900 shares. 2 times new highs have been achieved over the past 5 days, with a -$3.91 fall in that time frame. In the last twenty days, the average volume was 4,399,795, while in the previous 50 days, it was 3,883,530.
Since last month, NVO stock retreated -3.91%. Shares of the company fell to $90.50 on 09/21/23, the lowest level in the past month. A 52-week high of $100.88 was reached on 09/11/23 after having rallying from a 52-week low of $47.51. Since the beginning of this year, NVO’s stock price has risen by 34.92% or $23.63, and marked a new high 31 times. However, the stock has declined by -9.50% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Right now, Novo Nordisk A/S (NVO) has a P/E ratio of about 21.57. The stock’s beta is 0.45. Besides these, the trailing price-to-sales (P/S) ratio of 11.26, the price-to-book (PB) ratio of 31.70.
The latest dividend of $0.2209 per share was paid out, which is -25.67% less than last year’s $0.2972. On Thursday August 10 2023, a $0.0763 dividend decrease was announced.
Financial Health
In the three months ended June 29, Novo Nordisk A/S’s quick ratio stood at 0.70, while its current ratio was 0.90, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.21, and the total debt-to-equity ratio was 0.28. On the profitability front, the trailing twelve-month gross margin is 84.40% percent. In the year ended June 29, EBITDA margin amounted to 45.79%, whereas operating margins totaled 42.80%. Based on annual data, NVO earned $21.03 billion in gross profit and brought in $25.06 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 56.10%. Return on equity (ROE) for the past 12 months was 81.40%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected Novo Nordisk A/S to report $0.63 quarterly earnings, the actual figure was $1.24 per share, beating the consensus estimate by 96.80%. During the quarter, the company generated $3.81 billion in EBITDA. The liabilities of Novo Nordisk A/S were 27.8 billion at the end of its most recent quarter ended June 29, and its total debt was $25.7 billion.
Technical Picture
This quick technical analysis looks at Novo Nordisk A/S’s (NVO) price momentum. With a historical volatility rate of 21.50%, the RSI 9-day stood at 36.56% on 22 September.
With respect to its five-day moving average, the current Novo Nordisk A/S price is down by -4.11% percent or -$3.91. At present, NVO shares trade -1.48% below its 20-day simple moving average and +9.07% percent above its 100-day simple moving average. However, the stock is currently trading approximately +16.39% above its SMA50 and +43.69% above its SMA200.
Stochastic coefficient K was 15.30% and Stochastic coefficient D was 18.11%, while ATR was 2.31. Given the Stochastic reading of 7.73% for the 14-day period, the RSI (14) reading has been calculated as 44.57%. As of today, the MACD Oscillator reading stands at -2.06, while the 14-day reading stands at -3.01.
Analyst Ratings
HSBC Securities launched its rating on Novo Nordisk A/S (NYSE: NVO) to a Buy in a note to investors on July 14, 2023. Novo Nordisk A/S (NVO) has been rated Overweight by analysts. According to 4 brokerage firms, NVO is a sell, and 6 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Novo Nordisk A/S stock as buy, with 15 recommending it as overweight.
With a median target price of $202.40, the current consensus forecast for the stock is $102.96 – $235.00. Based on these forecasts, analysts predict Novo Nordisk A/S (NVO) will achieve an average price target of $191.75.
